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Abstract 
Background: Polypharmacy is often prescribed for bipolar disorder, yet medication non-adherence remains a serious 
problem. This study investigated the regularity in the daily dosage taken of mood stabilizers and second generation 
antipsychotics.
Methods: Daily self-reported data on medications taken and mood were available from 241 patients with a diagnosis 
of bipolar disorder who received treatment as usual. Patients who took the same mood stabilizer or second genera-
tion antipsychotic for ≥ 100 days were included. Approximate entropy was used to determine serial regularity in 
daily dosage taken. Generalized estimating equations were used to estimate if demographic or clinical variables were 
associated with regularity.
Results: There were 422 analysis periods available from the 241 patients. Patients took drugs on 84.4% of days. Con-
siderable irregularity was found, mostly due to single-day omissions and dosage changes. Drug holidays (missing 3 
or more consecutive days) were found in 35.8% of the analysis periods. Irregularity was associated with an increasing 
total number of psychotropic drugs taken (p = 0.009), the pill burden (p = 0.026), and the percent of days depressed 
(p = 0.049).
Conclusion: Despite low missing percent of days, daily drug dosage may be irregular primarily due to single day 
omissions and dosage changes. Drug holidays are common. Physicians should expect to see partial adherence in 
clinical practice, especially with complex drug regimens. Daily dosage irregularity may impact the continuity of drug 
action, contribute to individual variation in treatment response, and needs further study.
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Background
Drug regimens for the treatment of bipolar disorder 
are increasing in complexity. Polypharmacy, defined as 
two or more psychotropic medications, is prescribed 
to the majority of inpatients and outpatients, includ-
ing the elderly (Weinstock et  al. 2014; Bjørklund et  al. 
2016; Bauer et  al. 2013a; Peselow et  al. 2016; Kleimann 
et  al. 2016; Golden et  al. 2017; Rej et  al. 2017; Kessing 
et  al. 2016). A minority of patients, ranging from 18 to 
36% in recent studies, are prescribed four or more psy-
chotropic medications (Bauer et  al. 2013a; Weinstock 
et  al. 2014; Golden et  al. 2017; Goldberg et  al. 2009). 
The use of evidence-based combination therapies may 
improve treatment response, and many drug combina-
tions are included as first and second-line recommen-
dations in international guidelines for the treatment of 
bipolar disorder (Parker et  al. 2017; Fountoulakis et  al. 
2017). The challenges of polypharmacy include unproven 
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combination therapies, limited available evidence, 
increased risks of serious adverse reactions and drug 
interactions, and patient costs (Kukreja et al. 2013; Sachs 
et al. 2014).
Less than half of patients with bipolar disorder are 
estimated to be adherent with prescribed treatments, 
with most having intermittent or partial adherence that 
fluctuates over time (García et  al. 2016; Pompili et  al. 
2009; Scott and Pope 2002; Kessing et  al. 2007). Medi-
cation non-adherence in bipolar disorder is associated 
with an increased risk of relapse, hospitalization, and 
suicide (Hassan and Lage 2009; Hong et  al. 2011; Gon-
zalez-Pinto et al. 2006; Schuepbach et al. 2008). Medica-
tion adherence is difficult to measure, and all methods 
have strengths and weaknesses (Hawkshead and Krou-
sel-Wood 2007; Pearson et  al. 2007; Levin et  al. 2015; 
Sajatovic et al. 2010). Clinical studies of adherence gen-
erally involve subjective scales completed by patients or 
physicians, which quantify missing days, doses or atti-
tudes (Pompili et al. 2009; Baldessarini et al. 2008; Jóns-
dóttir et al. 2010). We previously measured the regularity 
in the daily dosage taken of mood stabilizers (lithium and 
anticonvulsants) using self-reported data (Bauer et  al. 
2013b). Dosage regularity measures daily changes and 
enhances understanding beyond the basic percent of 
missing days. Considerable irregularity in the daily dos-
age of mood stabilizers was found in patients missing 
less than 14% of days (Bauer et al. 2013b). Both the total 
number of psychotropic medications and the pill burden 
were associated with increased irregularity. The purpose 
of this study is to repeat the regularity analysis including 
second-generation antipsychotics as well as traditional 
mood stabilizers.
Methods
All data were obtained from outpatients, aged 18  years 
or older, who agreed to record mood, sleep, and medica-
tions taken daily using ChronoRecord software (Bauer 
et  al. 2004, 2008). All the participants were volunteers, 
primarily recruited by the prescribing psychiatrist, who 
were informed about the study prior to providing writ-
ten informed consent. The study was approved by local 
institutional review boards. The diagnosis was made 
by the prescribing psychiatrist at a clinical interview, 
and the patient received pharmacological treatment as 
usual throughout the study. Data were obtained from 
666 patients, of which 480 had a diagnosis of any bipo-
lar disorder based on DSM IV or DSM 5 criteria, and 
returned ≥ 30 days of data.
Patient data entry
Patents received about a half hour of training on the use 
of ChronoRecord software, in person or by telephone, 
before entering data. During the training session, a medi-
cation list was created for each patient. The medication 
list includes all drugs prescribed for bipolar disorder and 
any other prescribed or over-the-counter (OTC) drugs 
that the patient felt impacted their mood. The prescribed 
psychotropic drugs were selected from a list in the soft-
ware, displayed by both brand and generic names. The 
patient could add a drug not included in the software list, 
and could modify the list of drugs taken at any time. For 
each selected drug, the pill strength was chosen from a 
list of available strengths. Every day, for each drug, the 
patient entered the total number of pills taken. Patients 
could enter partial pills (1/4, 1/2, or 3/4) for tablets but 
not capsules. If a drug was not taken, the patient entered 
0 pills for that drug for that day. A missing day of data 
was also treated as if no pills were taken. Data not entered 
on 1  day could be entered at a later date. The software 
includes error checking to prevent entry for a future date, 
and to verify entry of a large number of pills for a drug.
In addition to medications, the patients entered mood, 
sleep, and significant life events daily, and weight weekly 
into the ChronoRecord software. ChronoRecord uses 
a 100-unit visual analog scale between the extremes of 
mania and depression to rate mood. Based upon the prior 
validation studies (Bauer et al. 2004, 2008), a mood entry 
less than 40 was considered depression, 40–60 euthymia, 
and greater than 60 hypomania/mania. The depression 
ratings varied from mild (entry of 20–39) to moderate–
severe (entry of 0–19), and the mania ratings varied from 
hypomania (entry of 61–80) to moderate-severe (entry of 
81–100).
Drugs analyzed
The drugs analyzed were traditional mood stabilizers 
as in the prior analysis: lithium, valproate, lamotrigine, 
carbamazepine, oxcarbazepine (Bauer et  al. 2013b), and 
second generation antipsychotics: aripiprazole, olanzap-
ine, risperidone, quetiapine, ziprasidone, paliperidone, 
asenapine, lurasidone, and clozapine. The analysis of the 
total psychotropic drugs taken and the daily pill burden 
also included antidepressants, benzodiazepines, typical 
antipsychotics, insomnia medications, other anticonvul-
sants (topirimate, gabapentin, pregabalin, tiagabine, leve-
tiracetam, zonisamide), thyroid hormones and estrogens.
Regularity analysis using ApEn
Regularity in the daily medication dosage was calculated 
using Approximate Entropy (ApEn) as in the prior stud-
ies (Bauer et  al. 2013b, c). ApEn is a family of statistics 
that measure serial regularity in a time series, are model 
independent, and can be used with datasets that are small 
and noisy (Pincus 1991; Pincus et  al. 1991). Regularity 
can be thought of as the tendency that values within a 
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time series remain the same on incremental comparisons 
(Pincus 1991; Pincus et al. 1991). ApEn computes a sin-
gle positive value, with 0 indicating a completely regular 
sequence, and with increasingly larger numbers signify-
ing greater serial irregularity. The estimated value of the 
ApEn (m, r, N) depends on: m the pattern length used for 
prediction of the subsequent value, r the level of noise 
filtering, and N the number of data values in the run to 
be compared. The ApEn noise filtering compares the dif-
ference between the data in each sequence of m days of 
data (Pincus et  al. 1991). Conceptually, when the abso-
lute value of the difference is greater than the noise fil-
ter level, the ApEn statistic is incremented. Otherwise, 
the difference is treated as noise and ignored. The level of 
noise filtering was calculated as a percent of the individ-
ual subjects’ standard deviation (Pincus et al. 1993). For 
this analysis, the parameters included were m  =  1  day, 
r = 0.2 × SD in daily drug dosage, and N = 100 days.
The calculated value of ApEn is dependent upon the 
order of the data in the time series. Changing the order of 
the data will likely change the calculated value of ApEn. 
In contrast, the calculated value of the familiar mean and 
standard deviation will be identical for a set of data in a 
time series regardless of the order of the data. ApEn is a 
valuable measure of the daily dosage fluctuations found 
with partial adherence (Bauer et al. 2013b, c). For exam-
ple, the ApEn would be 0 if the patient made no changes 
to the daily dosage or discontinued a medication, and 
would be largely unaffected by a prescription change 
if the patient keeps taking the new dosage (Bauer et  al. 
2013b).
Per patient regularity analysis
For every drug included in the ApEn analysis, the time 
span for taking the drug was determined for each patient. 
If the time span was ≥ 100 days, the ApEn was calculated 
for the first 100  days of data. Patients who took more 
than one drug for ≥ 100 days could have more than one 
ApEn analysis. Of the 480 patients with bipolar disorder, 
241 patients took at least one drug for sufficient length 
of time for analysis. For the 241 patients, 422 ApEn 
sequences were calculated.
Statistics
Descriptive statistics for the demographic and clinical 
characteristics of the 241 patients were calculated. For 
each patient, for each 100-day ApEn period, the percent 
of days with depressed, euthymic and manic/hypomanic 
mood were determined. Drug holidays, defined as miss-
ing 3 or more consecutive days (Urquhart 1998), were 
determined for each patient during the 100-day period. 
The daily pill burden was defined as total number of pills 
for all psychotropic medications. For each patient, for 
each 100-day ApEn period, the mode of the daily number 
of psychotropic medications, daily pill burden, and daily 
dosage were calculated. The mode is the most frequent 
value in a series of numbers, and was chosen as a proxy 
for the prescribed daily number of medications, pill bur-
den and daily dosage. The mean values for the entire 
sample were calculated using the modal values for each 
patient.
Since one patient could have more than one ApEn 
analysis, generalized estimating equations (GEE) were 
used to adjust model coefficients and standard errors for 
within-patient correlation. To estimate if demographic or 
clinical variables were associated with ApEn, GEE mod-
els were used with ApEn as the dependent variable and 
an independent working correlation structure (Pan and 
Connett 2002). GEE models were also used to estimate 
if demographic or clinical variables were associated with 
the percent of missing doses or with drug holidays. SPSS 
Version 24 was used for all analyses.
Results
422 ApEn sequences were calculated from the 241 
patients. Of the 241 patients, 158 (66%) were recruited 
from a university mood clinic and 83 (34%) from a pri-
vate practice. The demographic characteristics of the 241 
patients are shown in Table 1. During the 100-day peri-
ods, the patients were euthymic 71.6% of days, depressed 
20.9% of days, and hypomanic/manic 7.5% of days. The 
241 patients returned a mean of 389 (SD 567) days of 
data.
Medications
The medications taken by the 241 patients are summa-
rized in Table  2. The patients took a mean of 3.9 psy-
chotropic medications, with a mean pill burden of 7.2 
for these drugs. Many of the 241 patients were taking 
more than one mood stabilizer or antipsychotic, or 
changed medication, such that 121 (50%) of the patients 
had 1 ApEn analysis, 72 (30%) had 2 ApEn analysis, 40 
(17%) had 3 ApEn analyses, and 8 (3%) had  >  3 ApEn 
analyses.
Missing days and drug holidays
Overall, the patients took medication on a mean of 84.4% 
of days. Missing drug data occurred frequently within the 
100-day analysis periods. There was at least one single 
day omission in 64.7% of the 422 analyses periods. The 
percent of days of missing drug data was associated with 
the percent of days depressed (p = 0.046), and inversely 
associated with the percent of days euthymic (p = 0.047).
One or more drug holidays were found in 151 (35.8%) 
of the 422 analysis periods. Of the 151 analysis periods 
containing a drug holiday, more than one drug holiday 
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was present in 57 (37.8%). Taking a drug holiday was 
associated with working full time (p  =  0.005), and the 
total number of psychotropic drugs (p = 0.043).
Regularity analysis
For the 422 100-day analyses periods, the ApEn values 
ranged between 0 and 0.94, with a mean of 0.21 (SD 
0.18). For the 422 analyses, the ApEn was between 0 and 
0.2 for 240 (56.9%), between 0.2 and 0.4 for 128 (30.3%), 
and > 0.4 for 54 (12.8%). The ApEn was 0 (no change to 
daily dosage) in 56 (13.3%) of the analyses.
ApEn is directly related to the percent of days of miss-
ing doses (p < 0.001). However, even patients with a low 
percent of days missing doses may have irregular daily 
dosages. Figure  1 includes examples graphs of patients 
with irregular daily dosage, despite low missing days of 
data, and one example of how a patient may have both a 
larger number of missing days, and variable dosage.
The factors other than missing days of data that 
were associated with increasing irregularity are shown 
in Table  3. The total number of psychotropic drugs 
(p =  0.009), the pill burden (p =  0.026), and the per-
cent of days depressed (p =  0.049) were all associated 
with irregularity. The percent of days euthymic was 
inversely related to irregularity (p  =  0.028). No other 
clinical or demographic variables were associated with 
irregularity.
Table 1 Patient demographics (N = 241)
Demographic N %
Gender (N = 242)
 Male 70 29
 Female 171 71
Diagnosis (N = 240)
 BP I 145 60
 BP II 86 36
 BP NOS 9 4
Marital status (N = 223)
 Married 111 50
 Divorced 29 13
 Single 83 37
Employment status (N = 207)
 Working full-time 94 45
 Disabled 52 25
 Other 61 30
Education (N = 225)
 High school 29 13
 Some college 72 32
 College graduate 124 55
Mean SD
Age (N = 241) 41.2 10.9
Age of onset (N = 225) 22.6 10.5
Hospitalizations (N = 218) 2.8 4.7
Years of illness (N = 225) 18.9 12.1
Table 2 Psychotropic medications taken during the 100-day analyses periods (N = 241)
a Only psychotropic drugs 
b Only including drugs with ≥ 10 analysis periods
Medication N %
Taking antidepressants 122 51
Taking benzodiazepines 55 23
Taking insomnia medications 22 9
All  medicationsa Mean SD
Total number of medications 3.9 2.0
Total pill burden 7.2 4.8
Antipsychotic/mood  stabilizerb N in analysis Mean dosage (mg) Dosage SD Pct days missing
Aripiprazole 28 15.5 11.3 15.4
Risperidone 17 1.6 1.4 19.5
Quetiapine 48 268.4 202.0 22.3
Ziprasidone 12 141.6 59.4 12.9
Olanzapine 17 8.4 5.4 13.5
Lithium 99 914.6 320.6 15.1
Valproate 45 1107.2 599.0 12.8
Carbamazepine 15 798.1 386.1 5.1
Oxcarbazepine 14 938.1 605.6 26.1
Lamotrigine 119 231.9 129.4 13.5
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Discussion
Patients with bipolar disorder in this study were moti-
vated to actively participate in their care, and took medi-
cation on about 84% of days. Yet, even among this group, 
despite the low percent of missing days, there was consid-
erable irregularity in the daily dosage taken. Days of miss-
ing doses, primarily single day omissions, and changes to 
the daily dosage were the primary cause of the irregular-
ity. Additionally, there was at least one drug holiday in 
35.8% of the analysis periods. These results are consistent 
with our prior studies, and there are many implications of 
these findings (Bauer et al. 2013b, c).
It is challenging for the physician to reliably assess 
patient adherence and the link between non-adherence 
and inadequate response. Irregularity in the daily dosage 
may be a contributing factor. Most psychiatrists prefer 
to assess adherence of patients with bipolar disorder by 
asking the patient (Vieta et al. 2012), but physician per-
ceptions are often incorrect and optimistic (Velligan et al. 
2009; Baldessarini et  al. 2008). For example, physicians 
overestimated adherence with second-generation antip-
sychotics, primarily by patients with bipolar disorder, as 
compared to claims data (Stephenson et al. 2012). For 97 
patients who went to an emergency room for an exacer-
bation of psychosis, including 26 with bipolar disorder, 
staff assessments of adherence and non-adherence were 
correct 41.5 and 75% of the time respectively, when com-
pared to plasma antipsychotic levels (Lopez et al. 2017).
In this study, single day omissions occurred frequently. 
Some drugs and formulations are more forgiving about 
dosage omissions than others, varying with the pharma-
cokinetic and pharmacodynamic properties (Osterberg 
et  al. 2010; Urquhart 1998). With a forgiving drug, the 
duration of action is much longer than the dosage inter-
val, so an occasional missed dose is unlikely to interrupt 
therapeutic activity (Osterberg et al. 2010). Recently, the 
number of drug formulations that require less frequent 
dosing has increased, including formulations for psy-
chotropic drugs. While a less frequent dosing regimen 
generally increases adherence (Saini et al. 2009; Claxton 
et al. 2001), it may not improve outcomes (Comté et al. 
2007; Richter et al. 2003; Vrijens et al. 2014; Vrijens and 
Heidbuchel 2015; Harden 2017; Bialer 2007). For exam-
ple, the consequences of missing one dose of a once-
daily drug may be more deleterious to the continuity of 
therapeutic action than missing one dose of a twice-daily 
drug (Osterberg et al. 2010; Hughes 2006; Urquhart and 
Vrijens 2006). However, extended release formulations 
that reduce fluctuations in plasma concentration may 
improve the forgiveness of once-daily drugs (Pellock and 
Brittain 2016; Chen et  al. 2013; Brittain and Wheless 
2015).
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Fig. 1 Example ApEn, adherence and drug holiday values for 
100 days of data. In a–f, patients have few missing days but irregular 
daily dosage (high ApEn). In g, the patient has both a large number of 
missing days and irregular daily dosage. a Lamotrigine. ApEn 0.3432 
with 94% adherence and 0 drug holidays. b Valproate. ApEn 0.4836 
with 87% adherence and 2 drug holidays. c Lithium. ApEn 0.3511 
with 97% adherence and 0 drug holidays. d Risperidone. ApEn 0.6007 
with 80% adherence and 4 drug holidays. e Asenapine. ApEn 0.7117 
with 86% adherence and 1 drug holiday. f Lamotrigine. ApEn 0.3756 
with 99% adherence and 0 drug holidays. g Lamotrigine. ApEn 0.9428 
with 65% adherence and 4 drug holidays
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The relatively large number of drug holidays reported 
in this study, with a dosing interruption of 3 or more days, 
are of considerable concern. The rapid discontinuation of 
a psychotropic drug may trigger immediate withdrawal 
symptoms or delayed rebound phenomena, related to 
complex factors including pharmacokinetic and pharma-
codynamic properties of a drug formulation, and individ-
ual metabolism (Baldessarini et al. 1999; Cerovecki et al. 
2013; Franks et  al. 2008; Fava et  al. 2015; Correll 2010; 
Osterberg et  al. 2010). After a drug holiday, patients 
often resume taking the full-strength dosage, including of 
drugs that are slowly titrated upward. Re-starting a drug 
after a long lapse may trigger first-dose effects (Urquhart 
1998). Given the frequent use of polypharmacy, drug 
holidays may impact the potential for drug interactions 
(Spina et al. 2016). There is a need for increased under-
standing of the clinical impacts of repeated starting and 
stopping of mood stabilizers and antipsychotic drugs, 
in various product formulations (Osterberg et  al. 2010; 
Hughes 2008; Samtani et al. 2012). In this study, taking a 
drug holiday was associated with working full time, sug-
gesting that some patients may doubt they need ongoing 
treatment (Clatworthy et  al. 2009), or lack insight into 
the value of medications (Copeland et al. 2008). In prior 
research, employment was not associated with psycho-
tropic medication adherence (Bulloch and Patten 2010; 
Razzano et al. 2005, Sajatovic et al. 2006).
In addition to dosage omissions, changes to the daily 
dosage contributed to the irregularity. The patients in 
this study took polypharmacy with a mean of 3.9 psy-
chotropic medications for bipolar disorder, and a mean 
pill burden of 7.2. Both the number of psychotropic 
medications and the pill burden were associated with 
irregularity in daily dosage. Research in a wide range 
of chronic medical illnesses has found that medication 
regimen complexity decreases adherence (Ingersoll and 
Cohen 2008). Some patients with bipolar disorder may 
have trouble integrating a complex drug regimen into 
their daily routine (Sajatovic et  al. 2009; Wagner and 
Ryan 2004), especially those with a disorganized lifestyle 
(Frank et al. 2006). Even patients intent on adhering often 
forget about doses, especially on days with unexpected 
schedule interruptions (Dunbar-Jacob and Mortimer-
Stephens 2001; Bulloch and Patten 2010), which usually 
results in underdosing but sometimes overdosing.
Other factors contribute to irregular daily dosages. 
Patients may have an “as needed” approach to dosing, 
taking doses to treat symptoms or lessen side effects 
(Dunbar-Jacob and Mortimer-Stephens 2001; Marder 
2003; Pound et  al. 2005). Recent societal emphasis on 
self-management may be encouraging self-experimen-
tation (Swan 2013). Some patients want to take as little 
medication as possible (Pound et  al. 2005). Consistent 
with our prior studies, depressive symptoms were asso-
ciated with increased irregularity (Bauer et al. 2013b, c). 
In other research, depressive symptoms were associated 
with non-adherence in bipolar disorder (Belzeaux et  al. 
2013; Johnson et al. 2007), as well chronic medical condi-
tions (Grenard et al. 2011).
Several issues may impact the generalizability of this 
study. No data were available on the rate and character-
istics of patients who were asked but declined to par-
ticipate in the study. A large percentage of patients were 
recruited from university clinics, which may not reflect 
other settings. In the current study, more females than 
males were included, and patients varied in the phase of 
illness and disease severity. However, the demographic 
characteristics of the patients who use ChronoRecord are 
similar to those reported for other studies of bipolar dis-
order (Bauer et al. 2012). Since taking a mood stabilizer 
or antipsychotic for 100  days was required for analysis, 
the least adherent patients were excluded. However, even 
higher irregularity in daily dosage would be expected 
from patients who are less adherent.
There are other limitations to this study. All data 
were self-reported. However, review articles about the 
Table 3 Estimated coefficients of parameters associated with daily dosage irregularity for mood stabilizers and second 
generation  antipsychoticsa
a (422 100-day analyses periods). GEE model estimated ApEn (1, 0.2  * SD, 100) using the listed parameter with an independent working correlation structure for each 
model
b Psychotropic medications only
Parameter Coefficient estimate Standard error 95% Wald confidence interval Coefficient significance
Lower Upper Wald chi square p
Total pill  burdenb 0.005 0.002 0.001 0.010 4.944 0.026
Total number of  medicationsb 0.015 0.006 0.004 0.027 6.771 0.009
Percent days depressed 0.001 0.001 4.137E−6 0.003 3.867 0.049
Percent days euthymic − 0.001 0.001 − 0.002 0.000 4.845 0.028
Percent days manic 0.001 0.001 − 0.001 0.003 1.870 0.171
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measurement of medication adherence have found mod-
erate-to-high concordance between self-reported patient 
questionnaires and diaries, and electronic monitoring 
(Garber et al. 2004; Shi et al. 2010; Monnette et al. 2018). 
In a study of patients with bipolar disorder, good agree-
ment was found between patient questionnaires and serum 
levels of psychotropic medications (Jónsdóttir et al. 2010). 
This study underestimated regimen complexity since medi-
cations taken for general medical reasons and OTC drugs 
were not included. Other aspects of drug regimen com-
plexity such as administration instructions, and dosage 
timing were not available. Some of the dosage changes may 
have been prescribed by the physician. Only oral medica-
tions were included in this study. Different formulations of 
the same medication, such as pill size and ease of swallow-
ing, are known to impact adherence but were not consid-
ered (Bhosle et al. 2009; Fields et al. 2015). The specific drug 
regimens were not investigated but are highly variable in 
clinical practice, including different combinations of medi-
cation classes and drugs (Bauer et al. 2013a).
It is important to put the findings of this study into 
context. In this sample of patients with bipolar disorder 
who were motivated to participate in their care, there 
was considerable irregularity in daily dosage. However, 
partial adherence is also routinely found in patients with 
chronic medical conditions who do not have mental ill-
ness (Osterberg and Blaschke 2005; Brown et  al. 2016). 
Even in a monitored environment, less than 70% of over 
16,000 patients with various medical conditions enrolled 
in 95 clinical studies were fully adherent (Vrijens and 
Urquhart 2014; Blaschke et al. 2012). The clinician treat-
ing patients with bipolar disorder should expect a level 
of nonadherence including dosage omissions, changes, 
and drug holidays, even among patients determined to 
recover. If the patient’s condition is such that exceptional 
adherence is required, such as approaching no missing 
dosages, intensive educational measures, and customiza-
tion of the individual’s regimen are required. These find-
ings also confirm the need for careful evaluation of newly 
appearing or worsening symptoms.
Conclusion
In conclusion, considerable irregularity in daily dosage 
of mood stabilizers and antipsychotic medications was 
found despite a low percent of missing days. The total 
number of psychotropic drugs, pill burden and depres-
sion were associated with increased irregularity. The 
irregularity in daily dosage was primarily due to single 
day omissions and dosage changes. Drug holidays were 
also present. These findings may contribute to under-
standing the individual variation in treatment response 
seen in clinical practice. Physicians should expect to see 
partial adherence with treatments for bipolar disorder. 
More understanding of the impacts of daily irregularity 
on specific drugs and formulations is needed.
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